Hepatitis B Vaccine (HepB)

1. Basic Information

Disease Protected Against

Hepatitis B is a vaccine-preventable liver infection caused by the hepatitis B virus (HBV). It is transmitted through percutaneous or mucosal exposure to infected blood or body fluids. Modes of transmission include perinatal (mother-to-infant at birth), sexual contact, injection drug use, and household contact with an infected person. Hepatitis B can cause both acute and chronic infection. Chronic HBV infection occurs in ~90% of infants infected at birth, ~25–50% of children infected between ages 1–5, and ~5–10% of infected adults. Chronic infection can lead to cirrhosis, liver failure, and hepatocellular carcinoma (HCC), which is the 3rd leading cause of cancer death globally.

CDC Recommended Schedule (United States, 2025)

Source: CDC Advisory Committee on Immunization Practices (ACIP), 2025 Child & Adolescent and Adult Immunization Schedules.

Licensed Products (U.S.)

• Recombivax HB^® (Merck & Co.) — Licensed 1986. Recombinant DNA vaccine produced in Saccharomyces cerevisiae (yeast) expressing the hepatitis B surface antigen (HBsAg). First recombinant vaccine licensed for human use.
• Engerix-B^® (GlaxoSmithKline) — Licensed 1989. Also a recombinant HBsAg vaccine produced in yeast. Highly similar to Recombivax HB in composition and immunogenicity profile.
• Heplisav-B^® (Dynavax Technologies) — Licensed November 2017 for adults ≥18 years. Recombinant HBsAg vaccine adjuvanted with CpG 1018, a Toll-like receptor 9 (TLR9) agonist. 2-dose schedule (0 and 1 month) vs. 3-dose for older products. Higher seroprotection rates compared to Engerix-B in clinical trials.
• PreHevbrio^® (VBI Vaccines) — Licensed November 2021 for adults ≥18 years. Contains all three HBV surface antigens (S, pre-S1, pre-S2) produced in Chinese hamster ovary (CHO) cells. 3-dose schedule at 0, 1, and 6 months.
• Pediarix^® (GSK) — DTaP-HepB-IPV combination vaccine for infants. Licensed 2002. Not used for the birth dose.
• VAXELIS^® (Merck / Sanofi) — DTaP-IPV-Hib-HepB hexavalent combination vaccine for infants. Licensed 2018 in the U.S.

2. Pre-Licensure Clinical Trial Data

Recombivax HB^® & Engerix-B^® — Pivotal Trials (1980s)

The original plasma-derived hepatitis B vaccine was licensed in 1981; the recombinant vaccines (Recombivax HB and Engerix-B) replaced it in 1986 and 1989, respectively. Pre-licensure trials for the recombinant products enrolled several thousand participants cumulatively. The original Merck pivotal trial for Recombivax HB enrolled ~1,600 participants (including children and adults). Engerix-B trials were similarly sized and conducted internationally.

Heplisav-B^® (Dynavax) — Pivotal Trials for U.S. Licensure (2017)

Heplisav-B was evaluated in three Phase 3 non-inferiority trials (HBV-16, HBV-17, HBV-18) that compared a 2-dose regimen (0 and 1 month) of Heplisav-B to a 3-dose regimen (0, 1, and 6 months) of Engerix-B. A total of ~10,036 participants received Heplisav-B and ~4,596 received Engerix-B across these trials.

• Total Heplisav-B recipients in safety population: ~10,036 adults
• Seroprotection rate (Heplisav-B): 90–95% (non-inferior and in some analyses superior to Engerix-B, particularly in older adults and those with diabetes)
• Seroprotection rate (Engerix-B comparator): 70–90% across subgroups
• Safety follow-up: Solicited adverse events collected for 7 days; unsolicited AEs for 4 weeks; SAEs, AESIs, and deaths monitored for 12 months

Note: The FDA initially issued a Complete Response Letter (2013, 2016) requesting additional safety data before approving Heplisav-B in 2017, primarily regarding a numerical imbalance in acute myocardial infarction (MI) events observed in the clinical trial database (see Section 4).

PreHevbrio^® (VBI Vaccines) — Pivotal Trials for U.S. Licensure (2021)

PreHevbrio was evaluated in two Phase 3 trials (PROTECT and CONSTANT) that compared the 3-dose PreHevbrio regimen to a 3-dose regimen of Engerix-B. The combined safety population included ~3,700 participants who received PreHevbrio and ~1,300 who received Engerix-B.

• Total PreHevbrio recipients in safety population: ~3,700 adults aged 18–45 (PROTECT) and 18–80+ (CONSTANT)
• Seroprotection rate (PreHevbrio): ~91.4% vs. ~76.5% for Engerix-B (PROTECT study)
• Safety follow-up: Solicited AEs for 7 days; unsolicited AEs for 28 days; SAEs monitored for 6 months after last dose

Most Common Adverse Reactions (Pre-Licensure Trials)

Sources: Respective prescribing information / FDA review documents for Recombivax HB, Engerix-B, Heplisav-B, and PreHevbrio. Frequencies vary by trial design, age group, and dosage formulation.

Key Limitations of Pre-Licensure Trial Data

• Sample size: While larger than some older vaccine trials (especially Heplisav-B at ~10,000 recipients), pre-licensure trials are still underpowered to detect very rare adverse events (e.g., those occurring at rates <1 per 10,000 doses).
• Follow-up duration: Most trials had 6–12 months of formal safety follow-up, insufficient to assess long-term autoimmune or neurological outcomes with long latency periods.
• Exclusion criteria: Trials excluded pregnant individuals, immunocompromised persons, and individuals with significant chronic medical conditions, limiting generalizability to these groups.
• Era and design variability: The original recombinant vaccines (Recombivax HB, Engerix-B) were licensed using 1980s-era trial designs with less rigorous safety data collection standards than modern trials. Much of the safety evidence for these products derives from post-licensure studies.
• Myocardial infarction signal with Heplisav-B: In pre-licensure trials, a numerical imbalance in acute MI events was observed (19 events in Heplisav-B recipients vs. 3 in Engerix-B recipients across pooled Phase 3 data; 6 vs. 1 in the largest trial, HBV-23). This was a key reason for the FDA's initial Complete Response Letters. No causal mechanism was identified, and post-hoc analyses did not demonstrate a statistically significant difference after adjusting for baseline cardiovascular risk factors. Post-licensure studies are ongoing to further evaluate this signal (see Section 4).

3. Post-Licensure Safety Data

Vaccine Safety Datalink (VSD)

The VSD is a collaboration between the CDC and integrated healthcare organizations that monitor the electronic health records of approximately 9–10 million people annually (~3% of the U.S. population). HepB vaccines have been studied through VSD since the system's inception.

• Design: Active surveillance using electronic health records; includes both self-controlled case series, historical cohort studies, and rapid cycle analyses.
• Key VSD findings for hepatitis B vaccine:
  • Anaphylaxis: VSD data contributed to the estimated rate of ~1.1 per million doses (pooled across multiple vaccines in the Bohlke et al. 2003 study).
  • Multiple sclerosis: A large VSD nested case-control study (DeStefano et al., 2003) found no association between hepatitis B vaccination and MS (OR 0.9; 95% CI 0.6–1.4). A separate VSD study of relapse risk in patients with existing MS found no increased risk temporally associated with vaccination.
  • Central nervous system demyelinating disorders: VSD studies have not found consistent associations between hepatitis B vaccine and CNS demyelinating diseases beyond background rates.
  • Autoimmune conditions broadly: Systematic VSD reviews have not identified statistically significant associations between hepatitis B vaccination and rheumatoid arthritis, type 1 diabetes, or thyroiditis.
  • Neonatal / infant safety: VSD and other post-licensure studies have not identified unexpected safety signals in the newborn period following the birth dose.

Sources: DeStefano et al. (2003) Neurology; Bohlke et al. (2003) Pediatrics; VSD annual surveillance reports (CDC).

VAERS (Vaccine Adverse Event Reporting System)

VAERS is a passive (spontaneous) reporting system co-managed by the CDC and FDA. VAERS cannot establish causation. Reports may be submitted by anyone and reflect unverified temporal associations. Hepatitis B vaccine safety data in VAERS span >35 years of post-licensure experience, with billions of doses administered globally.

Major Independent Post-Licensure Reviews

The French Hepatitis B Vaccination Program and Subsequent Investigation

In the mid-1990s, France undertook a mass hepatitis B vaccination campaign targeting adults and adolescents (~20 million people vaccinated). Beginning in 1996, case reports of multiple sclerosis (MS) and other CNS demyelinating events temporally associated with hepatitis B vaccination were reported. This led to the suspension of the school-based vaccination program in 1998 (though infant vaccination continued). The signal prompted multiple large-scale epidemiological investigations:

• Conseil & Kerbrat (1998–2001): Multiple case-control and cohort studies in France, including a study of >15,000 MS cases, did not find a statistically significant association between hepatitis B vaccination and MS.
• Ascherio et al. (2001, New England Journal of Medicine): Nested case-control study using the Nurses' Health Study (n=121,700 women, 192 MS cases). Found no association between hepatitis B vaccination and risk of MS (RR 0.9; 95% CI 0.4–2.0).
• Confavreux et al. (2001, New England Journal of Medicine): European multi-center study of 643 MS patients. Hepatitis B vaccination did not increase the short-term risk of MS relapse (RR 0.71; 95% CI 0.40–1.26).
• DeStefano et al. (2003): VSD nested case-control study (440 MS cases). No association (OR 0.9; 95% CI 0.6–1.4).

The preponderance of evidence from multiple independent, well-designed studies did not confirm the hypothesis generated by case reports and VAERS reports. This episode is an illustrative example of the distinction between a safety signal (hypothesis-generating) and a confirmed causal association (requiring analytical epidemiological evidence). This is noted here because the French experience remains a reference point in discussions of hepatitis B vaccine safety.

Confirmed Safety Signals Identified in Post-Licensure Data

• Anaphylaxis: Confirmed causal association; estimated rate ~1.1 per million doses. Primarily in individuals with severe yeast sensitivity (the recombinant vaccines contain residual yeast protein).
• Heplisav-B and acute myocardial infarction: Pre-licensure safety signal (numerical imbalance). Post-licensure observational study by Klein et al. (2022, VSD) comparing Heplisav-B to Engerix-B among >38,000 adults found no statistically significant increased risk of acute MI following Heplisav-B compared to Engerix-B (adjusted HR 0.96; 95% CI 0.73–1.27). Active surveillance continues.

Note: Safety "signals" identified through post-licensure surveillance require further analytical epidemiological studies to confirm or refute causality. Signals may later be determined to be coincidental.

4. Documented Adverse Events — Evidence of Association

▶ Adverse Events with Strong Evidence of Causal Association

Criteria: Consistent epidemiological data from multiple independent studies, supported by mechanistic plausibility, and reviewed by IOM / NASEM or equivalent authoritative body.

• Anaphylaxis: Estimated at ~1.1 per million doses. Attributed to residual yeast proteins (Saccharomyces cerevisiae) in recombinant vaccines. Standard contraindication for individuals with known severe allergic reaction to yeast or a prior dose. Onset typically within minutes to hours of vaccination. Strong
• Injection site reactions (pain, erythema, swelling): Well-documented across all HepB vaccine products and age groups. Generally mild and self-limited (1–3 days). Higher rates reported with adjuvanted products (Heplisav-B, PreHevbrio) compared to non-adjuvanted (Engerix-B, Recombivax HB). Strong
• Systemic reactions (fatigue, headache, myalgia, fever): Consistently reported in clinical trials and post-licensure surveillance. Generally mild-to-moderate and self-limited. Higher rates with adjuvanted formulations. Strong

▶ Adverse Events with Moderate or Preliminary Evidence

Criteria: Some epidemiological evidence consistent with a signal, but data are limited by sample size, inconsistent findings across studies, or insufficient mechanistic evidence.

• Acute myocardial infarction (Heplisav-B specifically): Pre-licensure numerical imbalance (19 vs. 3 events in pooled trials; 6 vs. 1 in HBV-23). A large VSD post-licensure study (Klein et al., 2022; N >38,000) found no statistically significant association (HR 0.96; 95% CI 0.73–1.27). The FDA required a post-marketing safety study, which is ongoing. Moderate (against association, with ongoing monitoring)
• Guillain-Barré Syndrome (GBS): Isolated case reports exist following hepatitis B vaccination. IOM (2012) concluded evidence is inadequate to accept or reject a causal relationship. No consistent signal in large epidemiological studies. Limited
• Vasculitis / polyarteritis nodosa: A small number of case reports have described vasculitis temporally associated with hepatitis B vaccination. Evidence is insufficient to determine causality. Limited
• Chronic fatigue syndrome: Some case series have reported an association; controlled epidemiological studies have not demonstrated a significantly increased risk. IOM deemed evidence inadequate. Limited

▶ Published Evidence Does Not Support a Causal Association

Criteria: Multiple large, well-controlled epidemiological studies have consistently failed to find an association; IOM / NASEM has rejected a causal relationship; or the preponderance of high-quality evidence is against an association.

• Multiple Sclerosis (MS): Extensively studied following the French signal. Evidence against a causal association is robust. Major studies include:
  • Ascherio et al. (2001, NEJM): Nurses' Health Study; N=121,700; RR 0.9 (95% CI 0.4–2.0)
  • Confavreux et al. (2001, NEJM): European multi-center; N=643 MS patients; RR of relapse 0.71 (95% CI 0.40–1.26)
  • DeStefano et al. (2003, Neurology): VSD case-control; N=440 MS cases; OR 0.9 (95% CI 0.6–1.4)
  • Hernán et al. (2004, Neurology): UK General Practice Research Database; N=163 MS cases; OR 3.1 (95% CI 1.5–6.3) — an outlier finding not replicated in subsequent larger studies and deemed inconsistent with the broader evidence base by IOM
  • IOM (2012) concluded evidence "favors rejection" of a causal relationship
  No Association
• CNS demyelinating disorders broadly (optic neuritis, transverse myelitis, ADEM): VSD and several European studies have not found consistent associations. IOM (2012) favored rejection of causality for CNS demyelinating diseases in adults. Evidence in children is more limited but does not suggest a signal. No Association
• Rheumatoid Arthritis: A 2002 Swedish case-control study initially reported an association (OR 2.0), but multiple subsequent larger studies (including within VSD) failed to replicate. IOM (2012) favored rejection of causality. No Association
• Systemic Lupus Erythematosus (SLE): Case reports exist but controlled epidemiological studies have not demonstrated an association. IOM deemed evidence inadequate to infer a causal relationship; no replicated signal in large studies. No Association
• Type 1 Diabetes Mellitus: Multiple cohort studies have not found an association between hepatitis B vaccination and type 1 diabetes incidence. IOM (2012) favored rejection of causality. No Association
• Sudden Infant Death Syndrome (SIDS): The hepatitis B birth dose is administered within the first 24 hours of life, a period when SIDS risk in the neonatal period is inherently present. Multiple large studies and ecological analyses have not identified an association. WHO GACVS and IOM have concluded no causal association. No Association
• Thyroiditis / Autoimmune thyroid disease: Studied in VSD and European databases; no consistent association identified. No Association

5. Disease Prevention Benefits

5a. Hepatitis B — Pre-Vaccine vs. Post-Vaccine Era (United States)

Source: CDC MMWR surveillance summaries; CDC Pink Book (Hepatitis B chapter); McMahon et al. (Alaska longitudinal cohort); Chang et al. (Taiwan HCC data). Note: Estimated acute infections are ~5–6 times higher than reported cases due to asymptomatic infections and underreporting.

5b. Impact of Universal Infant Vaccination — U.S. and Global Data

• U.S. Acute HBV in children: Following the 1991 ACIP recommendation for universal infant hepatitis B vaccination, acute HBV infection in children and adolescents declined by >95% between 1990 and 2015. Reported cases in persons aged <20 years fell from ~3.6 per 100,000 (1990) to <0.02 per 100,000 (2015).
• Hepatocellular carcinoma: The hepatitis B vaccine was described by the WHO as the world's first "anti-cancer vaccine" because chronic HBV is the leading global cause of HCC. In Taiwan — the first country to implement universal infant vaccination (1984) — the incidence of HCC in children aged 6–14 years declined from 0.70 per 100,000 (1981–1986) to 0.57 (1986–1990) to 0.36 (1990–1994), representing a ~75% reduction in the vaccinated cohort (Chang et al., 1997, New England Journal of Medicine; updated in 2009).
• Global coverage: WHO estimates that global hepatitis B birth dose coverage was ~45% in 2022 (up from <5% in 2000), and 3-dose coverage was ~84% in 2022. An estimated 254 million people were living with chronic HBV infection globally in 2022, down from ~296 million in 2015, largely attributable to vaccination scale-up.
• Perinatal transmission: The combination of maternal HBsAg screening (U.S. recommended since 1988), HBIG, and birth-dose vaccination has reduced the rate of perinatal transmission in the U.S. from ~20–30% (no intervention) to <1% (with appropriate prophylaxis).

Sources: CDC Pink Book; Chang MH et al. N Engl J Med (1997, 2009); WHO Hepatitis B fact sheet (2024).

Current Disease Burden & Outbreak Context

• Acute hepatitis B (U.S.): Approximately 14,000–22,000 estimated acute infections occur annually, primarily in unvaccinated adults with risk factors (injection drug use, multiple sexual partners, men who have sex with men). Reported acute cases have remained relatively flat since 2010 after a long-term decline, and may be increasing slightly in some states affected by the opioid crisis (injection drug use is a major risk factor).
• Chronic hepatitis B (U.S.): An estimated 580,000–2.4 million persons in the U.S. have chronic HBV infection, depending on the estimation method. The wide range reflects uncertainty due to underdiagnosis and inclusion or exclusion of foreign-born populations. Only an estimated ~30–33% of persons with chronic HBV in the U.S. are aware of their infection.
• Health disparities: The prevalence of chronic HBV is substantially higher among foreign-born persons from endemic regions (Asia, sub-Saharan Africa, Pacific Islands) and among persons who inject drugs. U.S. vaccination policy focuses on catch-up vaccination in these populations as well as universal infant vaccination.
• Global burden: HBV is among the top 10 causes of death globally. In 2022, an estimated 1.1 million persons died from HBV-related causes, including cirrhosis and hepatocellular carcinoma, despite the availability of a highly effective vaccine.

6. Evidence Summary — Overall Assessment

Quality and Quantity of Safety Data

The hepatitis B vaccine has been in widespread use for >35 years, with >1 billion doses administered globally. The evidence base includes:

• Multiple randomized controlled trials for each licensed product, including modern large-scale Phase 3 programs for Heplisav-B (~10,000 recipients) and PreHevbrio (~3,700 recipients).
• Active surveillance through VSD spanning ~9–10 million persons annually and >30 years of continuous monitoring.
• Passive surveillance (VAERS) with >75,000 reports over >35 years.
• Targeted post-licensure epidemiological studies addressing specific safety concerns (MS, autoimmune disease, MI for Heplisav-B).
• Independent comprehensive reviews by IOM (2002, 2012), NASEM (2020), and WHO GACVS (ongoing).
• Long-term follow-up studies from Taiwan, Alaska, and other universal vaccination programs with >30 years of follow-up data.

Areas Where Data Are Robust

• Effectiveness (seroprotection): Large datasets consistently confirm >95% seroprotection after a complete 3-dose series in healthy infants, children, and young adults. Heplisav-B immunogenicity is non-inferior and in some subgroups superior to Engerix-B.
• Prevention of perinatal transmission: The effectiveness of birth dose + HBIG in preventing perinatal transmission (<1% transmission rate with appropriate PEP) is well-documented in multiple cohort studies.
• Anaphylaxis risk: Well-characterized, with a known mechanism (yeast allergy) and established risk estimate (~1.1 per million doses).
• Absence of MS association: Following the French signal, this question was investigated with multiple independent large-scale studies across several countries. The evidence is robust and consistent, and IOM has rejected a causal association.
• Absence of autoimmune disease cluster: The hypothesis generated by the French campaign has been tested in multiple controlled studies, and the preponderance of evidence does not support an association.
• Long-term cancer reduction: Taiwan and Alaska data provide direct epidemiological evidence of HCC reduction in vaccinated cohorts, with >30 years of follow-up.

Areas Where Data Are Limited or Conflicting

• Heplisav-B cardiovascular safety: The pre-licensure MI signal created uncertainty that post-licensure data have not fully resolved. The VSD study by Klein et al. (2022) was reassuring (HR 0.96; 95% CI 0.73–1.27), but the FDA-mandated post-marketing study is still ongoing. The evidence is trending against an association, but longer-term data with larger sample sizes are pending.
• Very rare neurological events (<1 per million): Similar to other vaccines, events like GBS or transverse myelitis occurring at very low rates are difficult to study with adequate statistical power. The evidence to exclude a very small increase in risk is inherently limited.
• Adverse events in immunocompromised populations: Hepatitis B vaccination is recommended for immunocompromised individuals (including those with HIV and chronic liver disease), but safety data specific to these groups are limited to small studies and post-hoc analyses. Immunogenicity is reduced in these populations, but adverse event profiles have not been thoroughly characterized relative to immunocompetent populations.
• Duration of protection: Studies indicate that protection lasts at least 30 years and possibly lifelong in immunocompetent individuals vaccinated as infants. The need for booster doses is not established for most populations, but long-term follow-up beyond 30 years is still accumulating.
• Combination vaccine safety: Pediarix and VAXELIS include HepB antigens with 4–5 other vaccine antigens. While overall safety profiles are comparable to separately administered components, studies designed specifically to parse HepB-attributable risk in these combinations are limited.
• Adjuvant-specific effects: Heplisav-B uses the CpG 1018 adjuvant (TLR9 agonist), and PreHevbrio uses aluminum hydroxide. The long-term safety profile of the novel CpG adjuvant relative to traditional aluminum adjuvants is still being characterized, with only ~7 years of post-licensure experience (licensed 2017) compared to >35 years for the aluminum-adjuvanted products.

Overall Summary Table

7. Key References

References are organised by category. Links are provided to the original source where available.

Pre-Licensure Trials / FDA Review Documents

1. Merck & Co., Inc. Recombivax HB^® (Hepatitis B Vaccine [Recombinant]) — Prescribing Information. merck.com
2. GlaxoSmithKline. Engerix-B^® (Hepatitis B Vaccine [Recombinant]) — Prescribing Information. gskpro.com
3. Dynavax Technologies Corporation. Heplisav-B^® (Hepatitis B Vaccine [Recombinant], Adjuvanted) — Prescribing Information. heplisavb.com
4. VBI Vaccines Inc. PreHevbrio^® (Hepatitis B Vaccine [Recombinant]) — Prescribing Information. prehevbrio.com
5. FDA. Clinical Review — Heplisav-B (BLA 125428), 2017. fda.gov/vaccines-blood-biologics/vaccines/heplisav-b
6. FDA. Clinical Review — PreHevbrio (BLA 125689), 2021. fda.gov

Institute of Medicine / National Academies Reports

7. Institute of Medicine. Adverse Effects of Vaccines: Evidence and Causality. Washington, DC: The National Academies Press; 2012. nationalacademies.org
8. Institute of Medicine. Hepatitis B Vaccine and Demyelinating Neurological Disorders. Washington, DC: The National Academies Press; 2002.
9. Committee on the Assessment of Studies of Health Outcomes Related to the Recommended Childhood Immunization Schedule. The Childhood Immunization Schedule and Safety. National Academies Press; 2013.

Major Post-Licensure Safety Studies — Multiple Sclerosis & Demyelinating Disease

10. Ascherio A, Zhang SM, Hernán MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med. 2001;344(5):327–332. DOI: 10.1056/NEJM200102013440502
11. Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med. 2001;344(5):319–326. DOI: 10.1056/NEJM200102013440501
12. DeStefano F, Verstraeten T, Jackson LA, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol. 2003;60(4):504–509. DOI: 10.1001/archneur.60.4.504
13. Hernán MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology. 2004;63(5):838–842. DOI: 10.1212/01.WNL.0000138433.61870.82

Heplisav-B Post-Licensure Safety

14. Klein NP, Goddard K, Lewis N, et al. Post-licensure safety surveillance of Heplisav-B and Engerix-B. JAMA. 2022;328(18):1834–1842. DOI: 10.1001/jama.2022.19356. Key finding: No statistically significant increased risk of acute MI with Heplisav-B vs. Engerix-B (HR 0.96; 95% CI 0.73–1.27).

Disease Burden & Vaccine Effectiveness

15. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med. 1997;336(26):1855–1859. DOI: 10.1056/NEJM199706263362602
16. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101(19):1348–1355. DOI: 10.1093/jnci/djp288
17. McMahon BJ, Bulkow LR, Singleton RJ, et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology. 2011;54(3):801–807. DOI: 10.1002/hep.24442
18. Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112(4):815–820. DOI: 10.1542/peds.112.4.815

Official Surveillance and Public Health References

19. CDC. Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book) — Hepatitis B chapter. cdc.gov/pinkbook
20. CDC. Vaccine Safety Datalink (VSD). cdc.gov/vaccine-safety/about/vsd.html
21. CDC/FDA. Vaccine Adverse Event Reporting System (VAERS). vaers.hhs.gov
22. CDC. 2025 Child & Adolescent Immunization Schedule. cdc.gov/vaccines/hcp/imz-schedules
23. WHO. Hepatitis B fact sheet (2024). who.int/news-room/fact-sheets/detail/hepatitis-b
24. WHO. Global Advisory Committee on Vaccine Safety (GACVS) — Hepatitis B vaccine safety statements. who.int